American Society of Hirudotherapy

Heparin-induced thrombocytopenia: natural history, diagnosis, and management

Review published in Vasc Med (2001)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentClinical TrialsDeitcher SR, Carman TL · Vascular medicine, 2001

Abstract

Heparin-induced thrombocytopenia (HIT) is an under-recognized, limb- and life-threatening complication of pharmacologic heparin administration. Antibody formation against heparin complexed to platelet factor 4 (PF4) is central to the pathogenesis of HIT. Heparin:PF4 antibodies promote platelet activation and aggregation as well as excess thrombin generation which may lead to clinical thrombosis. HIT should be suspected in patients who develop thrombocytopenia with or without associated arterial or venous thrombosis while on heparin. HIT is a clinical diagnosis. Specialized HIT assays should be interpreted with care. The cornerstone of HIT management is the discontinuation of all forms of heparin exposure and the institution of anticoagulation with an alternative agent. The direct thrombin inhibitors lepirudin and argatroban are currently available and approved for use in patients with HIT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsHeparinHumansThrombocytopenia

Summary

HIT review emphasizing PF4-heparin antibody pathogenesis and FDA-approved lepirudin and argatroban DTIs for HIT thrombosis management.

Why This Matters for Hirudotherapy

This review discusses the diagnosis and management of heparin-induced thrombocytopenia (HIT), described as a serious complication of heparin therapy caused by antibodies against heparin complexed to platelet factor 4 that promote platelet activation and excess thrombin generation. The abstract identifies direct thrombin inhibitors lepirudin and argatroban as currently available and approved alternative anticoagulants for HIT management, following discontinuation of all heparin exposure. While lepirudin is named as a treatment option, the abstract contains no mention of leeches, hirudin, or the leech secretome. No defensible leech or hirudotherapy connection can be drawn from the abstract alone; the article is focused on clinical HIT management.

Citation

Heparin-induced thrombocytopenia: natural history, diagnosis, and management.

Deitcher SR, Carman TL · Vascular medicine, 2001

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.